Administration of recombinant IFN-β, in the context of a randomized, double-blind, placebo-controlled clinical trial for the treatment of patients with active RA, however, showed no treatment effect on the clinical or radiographic scores [11]. This evidence concerns the gene IFNB1 and rheumatoid arthritis.